The Montreal Heart Institute (MHI) announced on November 16th,
2019 the results from the COLchicine Cardiovascular Outcomes Trial (COLCOT) which compared
colchicine to placebo on top of standard of care in preventing ischemic cardiovascular events
in patients with a recent myocardial infarction (MI). In this study, patients receiving colchicine
0.5mg daily had a significantly lower rate of first and total (first and recurrent) ischemic cardiovascular
events than those on placebo¹. These data were simultaneously published in the New England Journal of Medicine
(NEJM) and presented at the American Heart Association (AHA) late-breaking Scientific Session (AHA 2019 presentation).
The primary efficacy endpoint was a composite of cardiovascular death, resuscitated cardiac arrest, MI, stroke or urgent hospitalization for angina requiring coronary revascularization¹. Patients were also treated according to national guidelines that included the intensive use of statins¹.
Treatment with colchicine resulted in a:
• 23% reduction in the risk of a first event of the primary efficacy endpoint; with event rates of 5.5% with colchicine and 7.1% with placebo (HR, 0.77; 95% CI, 0.61-0.96; p=0.02)¹.
• 34% reduction in the risk of total (first and recurrent) events of the primary efficacy endpoint (RR, 0.66, 95% CI, 0.51-0.86, p=0.002)¹.
• 29% reduction in the risk of a first event of the primary efficacy endpoint in patients who adhered to the protocol; with event rates of 5.1% with colchicine and 7.1% with placebo (HR, 0.71; 95% CI, 0.56-0.90)¹.
1. Tardif J-C, Kouz S, Waters D, et al. Efficacy and safety of low-dose colchicine after
myocardial infarction. N Engl J Med 2019. Available at www.nejm.org